Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13947388 | 1.00 | EGFR (0.48) | EGFRLMNAEPHX1ALDH1A1POLB | |
| SCHEMBL6748643 | 1.00 | EGFR (0.48) | EGFRLMNAEPHX1ALDH1A1POLB | |
| SCHEMBL1700981 | 0.86 | EGFR (0.54) | EGFRLMNAEPHX1ALDH1A1POLB | |
| SCHEMBL2534565 | 0.86 | EGFR (0.54) | EGFRLMNAEPHX1ALDH1A1POLB | |
| SCHEMBL9029656 | 0.83 | CNR2 (0.46) | EGFRLMNAEPHX1POLBCNR1 | |
| SCHEMBL9029651 | 0.83 | CNR2 (0.46) | EGFRLMNAEPHX1POLBCNR1 | |
| SCHEMBL8183701 | 0.78 | — | — | |
| SCHEMBL25053038 | 0.77 | EGFR (0.47) | EGFRLMNAEPHX1ALDH1A1POLB | |
| SCHEMBL19669756 | 0.77 | EGFR (0.47) | EGFRLMNAEPHX1ALDH1A1POLB | |
| SCHEMBL7761589 | 0.77 | EGFR (0.52) | EGFRLMNAALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-1092729-B1 | POLYMERIZATION CATALYST, NOVEL TRANSITION METAL COMPOUND, AND POLYMERIZATION METHOD AND COPOLYMER USING THEM | MITSUI CHEMICALS INC (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-7482488-B2 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1048457-B1 | Lithographic printing plate precursor | FUJI PHOTO FILM CO LTD (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-1031414-B1 | Lithographic printing plate precursor | FUJI PHOTO FILM CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6703459-B1 | ORGANIC TRANSITION METAL COMPLEXES HAVING SPECIFIC STRUCTURE, WHICH CAN FORM COPOLYMERS HAVING LINKAGE FORMED BY MIGRATION OF ACTIVE HYDROGEN OF UNSATURATED MONOMER | MITSUI CHEMICALS, INC. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-6509132-B1 | Comprises an ink-receptive image area for receiving ink during the printing process and a hydrophilic non-image area for receiving fountain solution | FUJI PHOTO FILM CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| US-6455224-B1 | SUPPORT WITH HYDROPHILIC SURFACE AND PHOTOSENSITIVE LAYER CONTAINING INFRARED ABSORBENT WHICH CHANGES FROM HYDROPHILIC TO HYDROPHOBIC BY HEAT AND HYDROPHILIC POLYMER HAVING FUNCTIONAL GROUP RENDERING LAYER WATER DEVELOPABLE | FUJI PHOTO FILM CO., LTD. (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-1092729-A1 | POLYMERIZATION CATALYST, NOVEL TRANSITION METAL COMPOUND, AND POLYMERIZATION METHOD AND COPOLYMER USING THEM | Mitsui Chemicals, Inc. (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-1048457-A2 | Lithographic printing plate precursor | FUJI PHOTO FILM CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-1031414-A1 | Lithographic printing plate precursor | FUJI PHOTO FILM CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | EGFR 4608/4885LMNA 1909/4885EPHX1 372/4885 |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | EGFR 888/4885LMNA 2523/4885EPHX1 3978/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | EGFR 2573/4885LMNA 4383/4885EPHX1 3884/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | EGFR 4534/4885LMNA 2058/4885EPHX1 449/4885 |
| US-10696675-B2 | Imidazopyridopyrimidine derivative compound and use thereof | FGFR1, FGFR4, FGFR3 | EGFR 16/4885LMNA 4821/4885EPHX1 2766/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | EGFR 4608/4885LMNA 1909/4885EPHX1 372/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | EGFR 1162/4885LMNA 3737/4885EPHX1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.